Larralde M. Langerhans cell histiocytosis in children under one year // Arch. Argent. Pediatr. 2008. Vol. 106. N. 3. P. 269–272.
Leung M.B.D. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation // Imunnol. Rev. 2011. Vol. 242. N. 1. P. 233–246.
Levin J., Friedlander S.F., Del Rosso J.Q. Atopic dermatitis and the stratum corneum — part 1: the role of filaggrin in the stratum corneum barrier and atopic skin // J. Clin. Aesthet. Dermatol. 2013. Vol. 6. N. 10. P. 16–22.
Levin J., Friedlander S.F., Del Rosso J.Q. Atopic dermatitis and the stratum corneum — part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin // J. Clin. Aesthet. Dermatol. 2013. Vol. 6. N. 11. P. 49–54.
Lyons J.J., Milner J.D., Stone K.D. Atopic dermatitis in children: clinical features, pathophysiology, and treatment // Immunol. Allergy Clin. North Am. 2015. Vol. 35. N 1. P. 161–183.
McGrath J.A. Filaggrin and skin barrier defects // Australas. J. Dermatol. 2008. Vol. 49. P. 67–74.
Minkov M. Multisystem Langerhans cell histiocytosis in children // Paediatr. Drugs. 2011. Vol. 13. N. 2. P. 75–86.
Mohan G.C., Lio P.A. Comparison of dermatology and allergy guidelines for atopic dermatitis management // JAMA Dermatol. 2015. Vol. 151. P. 1009–1013.
Mori T., Ishida K., Mukumoto S. et al. Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitis // Br. J. Dermatol. 2010. Vol. 162. N. 1. P. 83–90.
Morizane S., Yamasaki K., Kajita A. et al. TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis // J. Allergy Clin. Immunol. 2012. Vol. 130. N. 1. P. 259–261.
Nidner R. Therapy with systemic glucocorticoids // Hautartzt. 2001. Vol. 52. P. 1062–1071.
Novak N., Simon D. Atopic dermatitis — from new pathophysiologic insights to individualized therapy // Allergy. 2011. Vol. 66. P. 830–839.
Nowicka D., Grywalska E. The role of immune defects and colonization of Staphylococcus aureus in the pathogenesis of atopic dermatitis // Anal. Cell. Pathol. (Amst.). 2018. Vol. 2018. Article ID 1956403.
Oji V., Eckl K.M., Aufenvenne K. et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease // Am. J. Hum. Genet. 2010. Vol. 87. N. 2. P. 274–281.
Otsuka A., Nomura T., Rerknimitr P. et al. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis // Immunol. Rev. 2017. Vol. 278. N. 1. P. 246–262.
Paller A.S., Siegfried E.C., Thaçi D. et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial // J. Am. Acad. Dermatol. 2020. Vol. 83. N. 5. P. 1282–1293.
Paller A.S., Tom W.L., Lebwohl M.G. et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults // J. Am. Acad. Dermatol. 2016. Vol. 75. N. 3. P. 494–503.
Parker J.J., Sugarman J.L., Silverberg N.B. et al. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children // Pediatr. Dermatol. 2021. Vol. 38. P. 1500–1505. DOI: https://doi.org/10.1111/pde.14820.
Peng W., Novak N. Pathogenesis of atopic dermatitis // Clin. Exp. Allergy. 2015. Vol. 45. N. 3. P. 566–574.
Puar N., Chovatiya R., Paller A.S. New treatments in atopic dermatitis // Ann. Allergy Asthma Immunol. 2021. Vol. 126. N 1. P. 21–31.
Rerknimitr P., Otsuka A., Nakashima C., Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus // Inflamm. Regen. 2017. Vol. 37. N. 1. P. 14.
Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I // J. Eur. Acad. Dermatol. Venereol. 2012. Vol. 26. N. 8. P. 1045–1060.
Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II // J. Eur. Acad. Dermatol. Venereol. 2012. Vol. 26. N. 9. P. 1176–1193.
Samuelov L., Sarig O., Harmon R.M. et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting // Nat. Genet. 2013. Vol. 45. N. 10. P. 1244–1248.
Scharschmidt T.C., Man M.-Q., Hatano Y. et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens // J. Allergy Clin. Immunol. 2009. Vol. 124. N. 3. P. 496–506.
Scheerer C., Eyerich K. Pathogenese des atopischen Ekzems // Hautarzt. 2018. Vol. 69. N. 3. P. 191–196.
Seegraber M., Srour J., Walter A. et al. Dupilumab for treatment of atopic dermatitis // Expert Rev. Clin. Pharmacol. 2018. Vol. 11. N. 5. P. 467–474.